Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer
Clinical and Translational Oncology, 06/13/2012
Jiang XD et al. – Recombinant human endostatin (RHES) “time window” is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours.



